Mylan launches generic Adcirca tablets
Mylan has gained Food and Drug Administration clearance for tadalafil tablets in a 20 mg dosage strength.
The product, which is the first generic version of Eli Lilly's Adcirca is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability.
"Mylan has a strong history of leading the way in creating important access to generic medicines, and we're excited to continue that tradition by offering the first generic to Adcirca tablets," Mylan CEO Heather Bresch said, in a press statement. "Mylan offers more than 650 products in the U.S., and the addition of tadalafil tablets strengthens our cardiovascular portfolio and commitment to these patients."
Tadalafil tablets had a market value of approximately $510 million for the 12 months ending May 31, 2018, according to IQVIA.
The product, which is the first generic version of Eli Lilly's Adcirca is indicated for the treatment of pulmonary arterial hypertension to improve exercise ability.
"Mylan has a strong history of leading the way in creating important access to generic medicines, and we're excited to continue that tradition by offering the first generic to Adcirca tablets," Mylan CEO Heather Bresch said, in a press statement. "Mylan offers more than 650 products in the U.S., and the addition of tadalafil tablets strengthens our cardiovascular portfolio and commitment to these patients."
Tadalafil tablets had a market value of approximately $510 million for the 12 months ending May 31, 2018, according to IQVIA.